scholarly journals Association of mean platelet volume and acute coronary syndrome

2017 ◽  
Vol 5 (4) ◽  
pp. 1217 ◽  
Author(s):  
Hasim Ahamed ◽  
Renoy A. Henry ◽  
Rema Pai
Keyword(s):  
Acute Coronary Syndrome ◽  
Chest Pain ◽  
Mean Platelet Volume ◽  
Coronary Thrombosis ◽  
Platelet Volume ◽  
Coronary Syndrome ◽  
Vessel Disease ◽  
Significant Difference ◽  
St Elevation ◽  
The Mean

Background: Acute coronary syndrome (ACS) is a set of signs and symptoms due to rupture of a plaque and are a consequence of platelet rich coronary thrombus formation. Larger platelets are haemostatically more active and and hence carry risk for developing coronary thrombosis leading to ACS. Platelet parameters especially mean platelet volume (MPV) could be used as an important and reliable marker in early detection of ACS when the patients come to emergency department with chest pain. The primary objective is to study the association between mean platelet volume and acute coronary syndrome. The secondary objectives are to analyse if there is a statistically significant difference in mean platelet volume between Non-ST elevation (NSTEMI) and ST-elevation Myocardial Infarction (STEMI) and between double vessel disease (DVD) and triple vessel disease (TVD).Methods: A total of 260 patients were included in the study depending on the inclusion and exclusion criteria. After dividing the patients with chest pain into control (Non-cardiac chest pain) and study group (ACS) which contained 130 each, venous blood was drawn and taken to haematology laboratory for analysis of MPV within 2 hrs. The statistical analysis used were mean, median, test of significance in difference (t-test) and chi-square test.Results: Mean platelet volume (MPV) was found to be higher among ACS patients (9.4868±0.85270) as compared to control (7.430±0.72172) and it was significant with a P value <0.05. It was also noticed that MPV was higher among patients with STEMI when compared to NSTEMI, 10.32±0.77932 and 9.22±0.52743 and it was statistically significant (P<0.05). Similarly, MPV between patients with triple and double vessel disease were compared and the mean MPV of 10.04±0.88738 of TVD was greater than the mean MPV of 9.22±0.67438 in DVD and was statistically significant (P<0.05).Conclusions: In this study the MPV was higher in patients with ACS than those in control group. The study also showed that there was significant difference in MPV values between people with STEMI and NSTEMI and between people with DVD and TVD. Hence it might be useful as an additional cost efficient test in conjunction with other markers in the early prediction of ACS in the emergency room. Larger platelets are haemostatically more active and hence carry risk for developing coronary thrombosis leading to ACS. Patients with increased MPV could be easily identified during routine haematological analysis and hence could play an important role in early detection of acute coronary syndrome (ACS).

scholarly journals Can Platelet/Mean Platelet Volume ratio, Neutrophil/lymphocyte ratio, and Procalcitonin used for Predicting Prognosis in Acute Coronary Syndrome?

2020 ◽  
Vol 1 (1) ◽  
pp. 4-10
Author(s):  
Sedat Özbay ◽  
Abuzer Coskun ◽  
Sevki Hakan Eren
Keyword(s):  
Acute Coronary Syndrome ◽  
Mean Platelet Volume ◽  
Volume Ratio ◽  
Mortality Rates ◽  
Platelet Volume ◽  
Mortality And Morbidity ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Coronary Syndrome ◽  
Vessel Disease

Objective: This study aimed to evaluate acute coronary syndrome (ACS), serum procalcitonin levels, Platelet/Mean Platelet Volume ratio (PMR) and Neutrophil/lymphocyte ratio (NLR) concerning post-myocardial infarction (MI) complications, mortality, and morbidity. Material and Method: The study included a total of 913 patients with ACS who presented to the emergency department with chest pain between January 2013 and December 2017. The patients were categorized as ST-elevated MI (STEMI), non-ST elevated MI (NSTEMI) and unstable angina (UA) according to the diagnosis. The demographic and laboratory characteristics of the patients were compared for three-vessel disease (TVD) and mortality rates. Result: Post MI complications, TVD, and mortality were significant among acute coronary syndrome groups. The three-vessel disease was mostly observed in anterior MI with a maximum rate of 58 (39.7%). Mortality was found as 23 (16.3%) in anterior MI and 18 (12.2%) in NSTEMI. Serum procalcitonin levels were highest in anterior MI. Platelet to Mean Platelet Volume ratio was higher in UA, whereas it was lower in STEMI and NSTEMI. Neutrophil to lymphocyte ratio was the lowest in UA. The cTn I values of STEMIs at 0, 6, 12 hours were higher than UA, and the 12th-hour cTnI values in anterior MI were higher than NSTEMIs. It was found that procalcitonin and NLR had a positive correlation with post-MI complications, mortality, and TVD, whereas PMR exhibited a negative correlation. Conclusion: The levels of procalcitonin, PMR, and NLR may be significant in respect of post-complications, mortality, and morbidity in acute coronary syndrome.

Prognostic Value of Mean Platelet Volume in Patients With Non-ST-Elevation Acute Coronary Syndrome

Angiology ◽  
2011 ◽  
Vol 63 (4) ◽  
pp. 241-244 ◽  
Author(s):  
Angel A. López-Cuenca ◽  
Antonio Tello-Montoliu ◽  
Vanessa Roldán ◽  
Patricio Pérez-Berbel ◽  
Mariano Valdés ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Mean Platelet Volume ◽  
Prognostic Value ◽  
Platelet Volume ◽  
Coronary Syndrome ◽  
St Elevation ◽  
Elevation Acute Coronary Syndrome

Comparison of prasugrel and ticagrelor for patient with acute coronary syndrome: a systematic review and meta-analysis

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
L.C.W Fong ◽  
N Lee ◽  
A.T Yan ◽  
M.Y Ng
Keyword(s):  
Acute Coronary Syndrome ◽  
Stent Thrombosis ◽  
Meta Analysis ◽  
Composite Endpoint ◽  
Cardiovascular Death ◽  
Coronary Syndrome ◽  
Primary Composite Endpoint ◽  
Significant Difference ◽  
St Elevation

Abstract Background Prasugrel and ticagrelor are both effective anti-platelet drugs for patients with acute coronary syndrome. However, there has been limited data on the direct comparison of prasugrel and ticagrelor until the recent ISAR-REACT 5 trial. Purpose To compare the efficacy of prasugrel and ticagrelor in patients with acute coronary syndrome with respect to the primary composite endpoint of myocardial infarction (MI), stroke or cardiac cardiovascular death, and secondary endpoints including MI, stroke, cardiovascular death, major bleeding (Bleeding Academic Research Consortium (BARC) type 2 or above), and stent thrombosis within 1 year. Methods Meta-analysis was performed on randomised controlled trials (RCT) up to December 2019 that randomised patients with acute coronary syndrome to either prasugrel or ticagrelor. RCTs were identified from Medline, Embase and ClinicalTrials.gov using Cochrane library CENTRAL by 2 independent reviewers with “prasugrel” and “ticagrelor” as search terms. Effect estimates with confidence intervals were generated using the random effects model by extracting outcome data from the RCTs to compare the primary and secondary clinical outcomes. Cochrane risk-of-bias tool for randomised trials (Ver 2.0) was used for assessment of all eligible RCTs. Results 411 reports were screened, and we identified 11 eligible RCTs with 6098 patients randomised to prasugrel (n=3050) or ticagrelor (n=3048). The included trials had a follow up period ranging from 1 day to 1 year. 330 events on the prasugrel arm and 408 events on the ticagrelor arm were recorded. There were some concerns over the integrity of allocation concealment over 7 trials otherwise risk of other bias was minimal. Patients had a mean age of 61±4 (76% male; 50% with ST elevation MI; 35% with non-ST elevation MI; 15% with unstable angina; 25% with diabetes mellitus; 64% with hypertension; 51% with hyperlipidaemia; 42% smokers). There was no significant difference in risk between the prasugrel group and the ticagrelor group on the primary composite endpoint (Figure 1) (Risk Ratio (RR)=1.17; 95% CI=0.97–1.41; p=0.10, I2=0%). There was no significant difference between the use of prasugrel and ticagrelor with respect to MI (RR=1.24; 95% CI=0.81–1.90; p=0.31); stroke (RR=1.05; 95% CI=0.66–1.67; p=0.84); cardiovascular death (RR=1.01; 95% CI=0.75–1.36; p=0.95); BARC type 2 or above bleeding (RR=1.17; 95% CI =0.90–1.54; p=0.24); stent thrombosis (RR=1.58; 95% CI =0.90–2.76; p=0.11). Conclusion Compared with ticagrelor, prasugrel did not reduce the primary composite endpoint of MI, stroke and cardiovascular death within 1 year. There was also no significant difference in the risk of MI, stroke, cardiovascular death, major bleeding and stent thrombosis respectively. Figure 1. Primary Objective Funding Acknowledgement Type of funding source: None

Sign in / Sign up

Export Citation Format

Share Document